This medicine is authorised for use in the European Union.


An overview of Xagrid and why it is authorised in the EU

Xagrid is a medicine used to reduce the number of platelets (components that help the blood to clot) in patients with essential thrombocythaemia (a disease in which there are too many platelets in the blood). ‘Essential’ means that the disease has no obvious cause.

Xagrid is used when patients do not respond to or do not tolerate their current treatment, and when they are ‘at risk’ because of their age (over 60 years), very high platelet counts or previous clotting problems.

Xagrid contains the active substance anagrelide.

This EPAR was last updated on 07/12/2018

Authorisation details

Product details
Agency product number
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
Thrombocythemia, Essential
Anatomical therapeutic chemical (ATC) code

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Publication details
Marketing-authorisation holder
Shire Pharmaceuticals Ireland Limited
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Block 2 & 3 Miesian Plaza
50-58 Baggot Street Lower
Dublin 2
D02 Y754

Product information

23/08/2018 Xagrid - EMEA/H/C/000480 - T/0082


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Xagrid is indicated for the reduction of elevated platelet counts in at-risk essential-thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.

An at-risk patient

An at-risk ET is defined by one or more of the following features:

  • >60 years of age or;
  • a platelet count >1000 x 109/l or;
  • a history of thrombohaemorrhagic events.

Assessment history

How useful was this page?

Add your rating